Getting Back Into CV?
Executive Summary
Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.
You may also be interested in...
IMPROVE-IT Go-Ahead Gives Merck Temporary Reprieve On Vytorin
Large outcomes study of Vytorin (ezetimibe/simvastatin) is allowed to carry on, reassuring investors that significant safety problems are unlikely to emerge. The development coincides with release of full results from the outcomes trial HPS2-THRIVE, in which Merck’s niacin-containing Tredaptive proved unsafe as well as ineffective.
Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial
With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.
Merck Continues Pursuit Of Cardiovascular Candidates With Theravance Partnership
The New Jersey-based big pharma continues to take shots on the cardiovascular goal, even after a string of failures in the space.